The European Commission’s Innovation Radar has highlighted two achievements of the ADDovenom project as ‘great EU-funded innovations’.
The ‘production of recombinant snake venom toxins for research and therapeutic purposes’ has been listed as ‘tech ready’ and as having a ‘”Noteworthy” level of Market Creation Potential’.
The ability to ‘generate highly specific protein scaffolds (ADDobodies) with high affinity against snake venom components’ was also described as ‘tech ready’ and as ‘addressing the needs of existing markets and existing customers’.
